Table 4 Association between characteristics of children and quality of care measured by lung function tests during follow-up in the months 7–12 after start of medication (n = 36,781)

P (No.)

PD (95% CI)

PR (95% CI)

Adj. PR (95% CI)

P-values

0.23 (3,317)

ref

1

1

0.25 (5,599)

0.02 (-0.0–0.03)

1.09 (1.05–1.13)

1.05 (1.01–1.09)

0.008

0.24 (4,380)

ref

1

1

0.25 (3,520)

0.01 (0.0–0.05)

1.02 (0.98–1.06)

1.07 (1.03–1.11)

0.001

0.21 (1,016)

-0.03 (-0.04- -0.02)

0.88 (0.83–0.94)

1.01 (0.95–1.07)

0.767

0.23 (1,515)

ref

1

1

0.25 (7,389)

0.02 (0.01–0.03)

1.08 (1.03–1.13)

1.06 (1.01–1.11)

0.020

1

0.24 (5,213)

ref

1

1

2

0.25 (2,542)

0.01 (0.0–0.02)

1.05 (1.01–1.1)

1.01 (0.97–1.06)

0.627

3

0.25 (1,149)

0.01 (0.0–0.03)

1.06 (1.0–1.12)

1.05 (0.99–1.11)

0.102

1

0.24 (1,378)

ref

1

1

2

0.24 (3,319)

0.00 (-0.02–0.01)

0.99 (0.94–1.05)

0.97 (0.91–1.02)

0.189

3

0.25 (2,942)

0.00 (-0.01–0.02)

1.01 (0.95–1.06)

0.97 (0.92–1.03)

0.288

4

0.24 (1,265)

-0.01 (-0.03–0.01)

0.96 (0.90–1.03)

0.92 (0.86–0.99)

0.018

0.14 (2,577)

ref

1

1

0.31 (4,090)

0.17 (0.16–0.17)

2.16 (2.06–2.25)

2.15 (2.06–2.24)

< 0.001

0.40 (2,249)

0.26 (0.25–0.27)

2.81 (2.68–2.95)

2.79 (2.66–2.93)

< 0.001